Antimicrobials · Cephalosporins
The facts most likely to be tested
Press 1–5 to rate · ↑↓ to navigate
Cefuroxime is a second-generation cephalosporin that provides expanded Gram-negative coverage compared to first-generation agents while maintaining efficacy against Gram-positive cocci.
The drug is one option for outpatient community-acquired pneumonia (CAP) in patients with comorbidities, but it should be combined with a macrolide or doxycycline for atypical coverage; IDSA/ATS (2019) does not recommend it as CAP monotherapy.
Cefuroxime is a standard treatment option for acute bacterial rhinosinusitis and acute otitis media in patients with penicillin allergies (non-anaphylactic).
Unlike first-generation cephalosporins, cefuroxime possesses increased stability against beta-lactamases produced by common respiratory pathogens.
Cefuroxime is an alternative for surgical prophylaxis in cardiothoracic surgery, but cefazolin remains the first-line agent, and orthopedic and cardiac operations are clean (not clean-contaminated) procedures.
The drug lacks activity against atypical pathogens such as Mycoplasma pneumoniae and Legionella pneumophila, necessitating combination therapy if these are suspected in pneumonia.
Cefuroxime does not provide coverage against Pseudomonas aeruginosa or anaerobes like Bacteroides fragilis.
Vignette unlocked
A 54-year-old male with a history of COPD presents with a 4-day history of productive cough, fever, and pleuritic chest pain. Physical examination reveals dullness to percussion and bronchial breath sounds in the right lower lobe. A chest X-ray confirms a lobar consolidation. The patient has a history of a mild maculopapular rash when taking amoxicillin in the past. He is hemodynamically stable and is being discharged for outpatient management.
Which of the following is the most appropriate antibiotic for this patient?
Cefuroxime plus azithromycin
The patient has CAP with comorbidities and a non-anaphylactic penicillin allergy, making a second-generation cephalosporin like cefuroxime an option; per IDSA, comorbid outpatient CAP also warrants atypical coverage, so add a macrolide or doxycycline (or use a respiratory fluoroquinolone).
Full handout
High yield triage
Classification
Second-generation cephalosporin; beta-lactam antibiotic.
Indications
Community-acquired pneumonia, acute otitis media, sinusitis, and Lyme disease.
Mechanism of Action
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs).
Side Effects
Diarrhea, nausea, and rash; anaphylaxis and C. difficile colitis.
Contraindications / Monitoring
History of severe hypersensitivity; monitor renal function (CrCl) for dosage adjustment.
Full handout
Mechanism of Action
Cefuroxime binds to specific penicillin-binding proteins (PBPs) located on the inner bacterial cell membrane. This binding inhibits the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defect leads to cell lysis and death. It maintains stability against many beta-lactamases compared to first-generation agents.
Unique Properties
Like other second-generation cephalosporins (the HENS PEcK mnemonic), cefuroxime adds activity against Haemophilus influenzae and Moraxella catarrhalis. Despite some blood-brain barrier penetration, cefuroxime causes delayed CSF sterilization and treatment failures in bacterial meningitis and should not be used for CNS infections.
Indications
It is one option for outpatient community-acquired pneumonia in patients with comorbidities (combined, per IDSA/ATS 2019, with a macrolide or doxycycline) and for acute bacterial sinusitis. It is also indicated for acute otitis media in patients who have failed first-line therapy. Additionally, it is an effective alternative for early Lyme disease in patients who cannot tolerate doxycycline.
Pharmacokinetics
Cefuroxime axetil is an oral prodrug that is hydrolyzed to active cefuroxime in the intestinal mucosa. It is primarily excreted unchanged by the kidneys via glomerular filtration and tubular secretion. Dosage adjustments are recommended in patients with significant renal impairment to prevent accumulation.
Side Effects & Adverse Events
Common adverse effects include gastrointestinal distress, specifically diarrhea and nausea. Patients may experience a maculopapular rash. Anaphylaxis is a rare but life-threatening hypersensitivity reaction. Clostridioides difficile-associated diarrhea is a serious risk following broad-spectrum antibiotic use.
Contraindications
The FDA label lists known hypersensitivity (e.g., anaphylaxis) to cefuroxime or to other beta-lactams (penicillins and cephalosporins) as a contraindication and warns that some patients with penicillin allergy have had severe reactions to cephalosporins. The AAAAI/ACAAI drug allergy practice parameter (2022) is less restrictive: after an unverified non-anaphylactic penicillin reaction, a cephalosporin can be administered without testing, and after penicillin anaphylaxis, a cephalosporin with a dissimilar R1 side chain can be administered without testing (conditional recommendations). A prior anaphylaxis to cefuroxime or to another cephalosporin generally warrants avoidance or allergist evaluation.
Monitoring
Monitor renal function (serum creatinine and calculated CrCl) periodically, especially in the elderly. Assess for signs of superinfection, such as persistent diarrhea or oral thrush. Evaluate for clinical improvement of the primary infection within 48-72 hours.
Clinical Pearls
Think of cefuroxime as the 'workhorse' for respiratory infections when H. influenzae is suspected. It is an accepted alternative for early Lyme disease in children or pregnant patients who cannot take tetracyclines, although amoxicillin is the usual first choice in those groups. For penicillin allergy, sources differ: the AAAAI/ACAAI drug allergy practice parameter (2022) favors side-chain-based rather than class-based avoidance (cefuroxime's R1 side chain differs from those of penicillin, ampicillin and amoxicillin), whereas the FDA cefuroxime label lists hypersensitivity to other beta-lactams, including penicillins, as a contraindication.